Industry News

UnitedHealth Group, are taking immediate action to help people in California who may be affected by the ongoing wildfires. This includes assisting health plan participants who may need to make alternate arrangements to ensure continuity of care and access to early prescription refills, as well as a free emotional-support line to help people in affected communities."/>
UnitedHealthcare and Optum Support People Affected by Wildfires in California
Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced the closing of its underwritten public offering of 1,986,666 shares of its common stock at a price to the public of $7.50 per share. The gross proceeds to Recro from the offering were approximately $15 million.."/>
Recro Pharma Announces Closing of Public Offering of Common Stock
Edge Therapeutics, Inc., a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Brian Leuthner, President and CEO, and Dr. R. Loch Macdonald, Chief Scientific Officer, will ring the Closing Bell."/>
Edge Therapeutics, Inc. (Nasdaq: EDGE) to Ring The Nasdaq Stock Market Closing Bell
Inovalon Holdings, Inc. shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company’ s common stock issued pursuant or traceable to Inovalon’ s February 12, 2015 initial public offering of common stock. FINAL REMINDER: Investors who purchased Inovalon common stock during the Class Period may, no later than August 23, 2016, petition the Court to be appointed as a lead plaintiff representative..."/>
Final Deadline Reminder for Inovalon Holdings, Inc. Shareholders
Lancashire Holdings was in focus on a quiet day in mid-August. The talk in the market is that a massive Canadian pension fund, thought to be Ontario Teachers' Pension Plan, approached the business before Britain's referendum on leaving the European Union about taking the company private. It is said that before Brexit, the fund had indicated it could be willing to offer about pounds sterling 1.3 bn or 618 p a share for Lancashire Holdings."/>
Daily Mail, London, market report column [Daily Mail, London]
SQI Diagnostics Inc. announced that it has successfully closed its previously announced rights offering, raising total gross proceeds of approximately $3,121,000.."/>
SQI Diagnostics Inc. Announces Closing of Rights Offering
Arch Therapeutics, Inc., a developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced its President and CEO, Terrence Norchi, MD conducted an interview with Dave Donlin, the host of' s "Small Cap Spotlight" podcast. Norchi discussed, the Company's lead product candidate, the AC5 Topical Hemostatic Device™, the results of the Company's recent clinical..."/>
Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire
Portola Pharmaceuticals Inc. ® today announced that the MAA for IndexXa™, a Factor Xa inhibitor antidote, has been submitted to the EMA, completed the validation period, and has been accepted for review. IndexXa is in development for patients treated with a Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery."/>
Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa™ (andexanet alfa), a Factor Xa Inhibitor Antidote
Advaxis, Inc. a clinical-stage biotechnology company developing cancer immunotherapies, is pleased to participate in Cervivor School in Louisville, Kentucky. Kim Dorney, MSN/RN, Associate Director of Clinical Operations for the upcoming AIM2CERV Phase 3 clinical study, will provide the opening keynote remarks during tonight's welcome dinner."/>
Advaxis to Participate in Cervivor School
Spectral Medical Inc., a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, confirms that its management and board of directors are unaware of any material, undisclosed corporate developments that would account for the recent decrease in its share price. As outlined in Spectral's press release dated August 18, 2016, the Company is on track with the regulatory pathway for..."/>
Spectral Unaware of Any Material Change
Aphria Inc. announced today that the Company entered into a purchase and sale agreement with DiNiro Farms Inc. to acquire 11 acres of additional property adjacent to its existing campus for a $2.1 million cash payment. The 11 acres of abutting property includes 345,000 square feet of existing greenhouses. Concurrent with this transaction, the abutting property will be merged into Aphria's existing municipal address, thereby avoiding the need..."/>
Aphria Accelerates Expansion Strategy
Kite Pharma, Inc. today announced that two of its key advisors and scientific collaborators, both pioneers in the field of cancer immunotherapy, have received the renowned Novartis Prize for Clinical Immunology. The winners were selected by an independent jury of seven world-class immunologists for their groundbreaking research into the biology of the immune system. Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute, and..."/>
Kite Pharma Advisors and Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award
Gilead Sciences Inc., Exelixis Inc., Ariad Pharmaceuticals Inc., and Novavax Inc.."/>
Research Report on Biotech Equities -- Gilead Sciences, Exelixis, Ariad Pharma, and Novavax
Helix BioPharma Corp., an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD1.0 million. The terms of the placement are for the purchase of units at $1.54 per unit. Each unit is comprised of one common share and one common share purchase warrant."/>
Helix BioPharma Corp. Closes CAD1.0 Million Private Placement
Mallinckrodt Pharmaceuticals, a leading global specialty pharmaceutical company, will present at the Wells Fargo Securities Healthcare Conference on Thursday, Sept. 8, 2016, at the Westin Boston Waterfront, 425 Summer St., in Boston, Mass. Mark Trudeau, President and Chief Executive Officer; Matthew Harbaugh, Senior Vice President and Chief Financial Officer; and Dr. Steven Romano, Senior Vice President and Chief Scientific..."/>
Mallinckrodt To Present At Wells Fargo Securities Healthcare Conference
Masimo reported on Thursday the receipt of CE Marking for RAS-45, a single-use adult and pediatric acoustic respiration sensor for rainbow Acoustic Monitoring of respiration rate. The Anesthesia Patient Safety Foundation and The Joint Commission reportedly recommend continuous oxygenation and ventilation monitoring for all patients receiving opioid-based pain medications. Using acoustic signal processing that..."/>
Masimo awarded CE Marking for RAS-45 for rainbow acoustic monitoring of respiration rate in patients receiving opioid-based pain medications
Alere Inc., a global leader in rapid diagnostics, today announced that its Alere™ i RSV test has received 510 marketing clearance from the U.S. Food and Drug Administration for the detection of RSV infection in children and adults. Following Alere™ i Influenza A& B and Alere™ i Strep A, Alere i RSV is the latest testing application on the Alere i platform and is the first molecular test that can be used at the point-of-care to detect RSV in 13 minutes or..."/>
Alere Receives FDA Clearance for Alere™ i RSV Rapid Molecular Test
Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, August 31, 2016 at 4.30 p.m. ET to discuss its second quarter financial results and provide an update on its vision and pipeline. A webcast of the conference call will be available on the..."/>
Ascendis Pharma A/S to Report Second Quarter 2016 Financial Results and Host Conference Call on August 31
Mesoblast Limited today announced it will report financial results for the fourth quarter and full year ended June 30, 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Wednesday, August 24, 2016 and 9:00 am Australian Eastern Standard Time on Thursday, August 25 2016.. To access the call, dial 1 855 881 1339, 1 800 558 698 or +61 2 9007 3187. The conference identification code is 262443.."/>
Mesoblast to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast
Innovus Pharmaceuticals, Inc., an emerging commercial stage cash flow positive pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories received the approval of the product licenses for Zestra ®, Zestra Glide ®, EjectDelay ® and Sensum+ ® from the Indian FDA, The Drugs..."/>
Innovus Pharma Announces the Approval of the Product Licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® by the Indian FDA (Directorate General of Health Services) through its Partner Khandelwal Laboratories
Derma Sciences revealed on Thursday the election of Russell Olsen as president of its advanced wound care. Currently, Olsen serves as president and chief executive officer of BioD, a regenerative medicine products company, which he joined in 2013.. Prior to the president and chief executive officer roles, Olsen has worked as chief operating officer at BioD."/>
Derma Sciences appoints Russell Olsen as president of advanced wound care
BD Celebrates 60 Years in Sandy, Utah
Valeant Pharmaceuticals International reported on Thursday the receipt of the requisite lender approval for an amendment to its credit facility. Subject to customary closing conditions, the company expects to close the amendment next week. Under the amendment, the company will reduce the interest coverage maintenance covenant to 2.0 x, provide additional headroom, provide additional flexibility to sell assets, permit the issuance of secured..."/>
Valeant Pharmaceuticals announces lender consent for amendment to credit facility
Wilson Therapeutics AB on Thursday reported a loss of SEK26.9m, or SEK1.66 per diluted share, for the second quarter of 2016, from 1 April 2016 to 30 June 2016.. This was a decline over loss of SEK16.7m or SEK13.14 per diluted share, in Q2 of 2015.. Net sales for the quarter were nil, the same as reported in Q2 2015.."/>
Wilson Therapeutics widens loss in Q2 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary535 Articles
Information Technology499 Articles
Financials424 Articles
Industrials321 Articles
Health Care286 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at